Efficacy and safety of elotuzumab for the treatment of multiple myeloma

References

• Kumar S, Rajkumar S, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J, Stoppa A, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Bertola A, et al. Multiple myeloma: comparison of two dose-intensive melphalan regimens [100 versus 200 mg/m (2)]. Leukemia. 2004;18:133–138.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895–905.
   PubMed Web of Science ®Google Scholar
• Gay F, Oliva S, Petrucci M, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase III trial. Lancet Oncol. 2015;16:1617–1629.
   PubMed Web of Science ®Google Scholar
• El-Amm J, Tabbara IA. Emerging therapies in multiple myeloma. Am J Clin Oncol. 2015;38(3):315–321. DOI:10.1097/COC.0b013e3182a4676b
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Richardson P, Moreau P, et al. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015b;12:42–54.
   PubMed Web of Science ®Google Scholar
• Lonial S, Durie B, Palumbo A, et al. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia. 2016;30(3):526–535.
   PubMed Web of Science ®Google Scholar
• Liu Y, Szmania S, van Rhee F. Profile of elotuzumab and its potential in the treatment of multiple myeloma. Blood Lymphat Cancer. 2014;2014:15–27.
   PubMedGoogle Scholar
• Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol. 2013;88(1):168–177.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276–2284.
   PubMed Web of Science ®Google Scholar
• Veillette A. SLAM-family receptors: immune regulators with or without SAP-family adaptors. Cold Spring Harb Perspect Biol. 2010;2:a002469.
   PubMed Web of Science ®Google Scholar
• Cannons J, Tangye S, Schwartzberg P. SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol. 2011;29:665–705.
   PubMed Web of Science ®Google Scholar
• Tai Y, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329–1337.
   PubMed Web of Science ®Google Scholar
• Tai YT, Soydan E, Song W, et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009;113(18):4309–4318. DOI:10.1182/blood-2008-10-183772
   PubMed Web of Science ®Google Scholar
• Cruz-Munoz ME, Dong Z, Shi X, et al. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol. 2009;10(3):297–305. DOI:10.1038/ni.1693
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775–2784. DOI:10.1158/1078-0432.CCR-07-4246
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania S, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8:2616–2624.
   PubMed Web of Science ®Google Scholar
• Perez-Quintero L, Roncagalli R, Guo H, et al. EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization. J Exp Med. 2014;211:727–742.
   PubMed Web of Science ®Google Scholar
• Clarkson N, Brown M. Inhibition and activation by CD244 depends on CD2 and phospholipase C-gamma1. J Biol Chem. 2009;284:24725–24734.
   PubMed Web of Science ®Google Scholar
• Collins S, Bakan C, Swartzel G, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62:1841–1849.
   PubMed Web of Science ®Google Scholar
• Roncagalli R, Taylor J, Zhang S, et al. Negative regulation of natural killer cell function by EAT-2, a SAP-related adaptor. Nat Immunol. 2005;6:1002–1010.
   PubMed Web of Science ®Google Scholar
• Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016;127(23):2833–2840.
   PubMed Web of Science ®Google Scholar
• Kim J, Mathew S, Patel R, et al. Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin Exp Immunol. 2010;160:348–358.
   PubMed Web of Science ®Google Scholar
• Neyer L, Ding H, Chen D, et al. Effect of elotuzumab on circulating lymphocytes, chemokines, and cytokines in multiple myeloma patients. Blood. 2010;116:4070.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621–631.
   PubMed Web of Science ®Google Scholar
• Lee J, Boles K, Mathew P. Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs. Eur J Immunol. 2004;34:2791–2799.
   PubMed Web of Science ®Google Scholar
• Balasa B, Yun R, Belmar N, et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunol Immunother. 2015;64:61–73.
   PubMed Web of Science ®Google Scholar
• Zonder J, Mohrbacher A, Singhal S, et al. A phase I, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120:552–559.
   PubMed Web of Science ®Google Scholar
• Jakubowiak A, Benson D, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30:1960–1965.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau J, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30:1953–1959.
   PubMed Web of Science ®Google Scholar
• Richardson P, Jagannath S, Moreau P, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase II results from the randomised, open-label, phase Ib-2 dose-escalation study. Lancet Haematol. 2015;2:e516–527.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Granell M, Oriol A, et al. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2016 Nov;175(3):448–456.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Lonial S, White D, et al. ELOQUENT-2 update: a phase III, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma – 3-year safety and efficacy follow-up. Blood. 2015a;126:28.
   Google Scholar
• Usmani SZ, Sexton R, Ailawadhi S, et al. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer J. 2015;5:e334. DOI: 10.1038/bcj.2015.62.
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22–32.
   PubMed Web of Science ®Google Scholar
• Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30(2):399–408.
   PubMed Web of Science ®Google Scholar
• Berdeja J, Jagannath S, Zonder J, et al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study. Clin Lymphoma Myeloma Leuk. 2015;16:129–138.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Miguel JS, Dimopoulos MA, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28(5):981–992.
   PubMed Web of Science ®Google Scholar
• van de Donk NWCJ, Kamps S, Mutis T, et al. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia. 2012;26(2):199–213.
   PubMed Web of Science ®Google Scholar
• Allegra A, Penna G, Alonci A, et al. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol. 2013;90(6):441–468.
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Anderson KC. Antibody-based therapies in multiple myeloma. Bone Marrow Res. 2011;2011:924058. doi: 10.1155/2011/924058. Epub 2011 Mar 2.
   Google Scholar
• Richardson PG, Lonial S, Jakubowiak AJ, et al. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2011;154(6):745–754.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A Phase I open label study of the safety and tolerability of elotuzumab (BMS-901608) administered in combination with either lirilumab (BMS-986015) or urelumab (BMS-663513) in subject with multiple myeloma (Study 028). NCT02252263. 2015 [cited 2016 Mar 4].
   Google Scholar
• ClinicalTrials.gov. Japanese study of (BMS-901608) (elotuzumab) in combination with lenalidomide and low dose dexamethasone. NCT01241292. 2015 [cited 2016 Mar 4].
   Google Scholar
• ClinicalTrials.gov. Elotuzumab in autologous stem cell transplantation (ASCT) and lenalidomide maintenance for multiple myeloma. NCT02655458. 2016 [cited 2016 Mar 4].
   Google Scholar
• ClinicalTrials.gov. Study of elotuzumab with lenalidomide as maintenanceafter autologous stem cell transplant (ASCT). NCT02420860. 2015 [cited 2016 Mar 4].
   Google Scholar
• ClinicalTrials.gov. Study of bortezomib, lenalidomide, dexamethasone & elotuzumab in newly diagnosed MM. NCT02375555. 2015 [cited 2016 Mar].
   Google Scholar
• ClinicalTrials.gov. Safety study of elotuzumab in combination with thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. NCT01632150. 2015 [cited 2016 Mar 4].
   Google Scholar
• ClinicalTrials.gov. Trial of elotuzumab with or without pomalidomideand low-dose dexamethasone to treat refractory and relapsed and refractory multiple myeloma. NCT02654132. 2015 [cited 2016 Feb 2].
   Google Scholar
• ClinicalTrials.gov. A study of Elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd) in patients with multiple myeloma relapsed or refractory to prior treatment with lenalidomide (Study 142) (NCT02612779). NCT02612779. 2015 [cited 2016 Mar 4].
   Google Scholar
• ClinicalTrials.gov. Biomarker study of elotuzumab in high risk smolderingmyeloma. NCT01441973. 2015 [cited 2016 Mar 4].
   Google Scholar
• ClinicalTrials.gov. Trial of combination of elotuzumab and lenalidomide± dexamethasone in high-risk smoldering multiple myeloma. NCT02279394. 2015 [cited 2016. Mar 4].
   Google Scholar
• ClinicalTrials.gov. PH III study of lenalidomide and dexamethasonewith and without elotuzumab to treat previously untreated multiplemyeloma (ELO 1 Sub study). NCT01891643. 2015 [cited 2016 Mar 4].
   Google Scholar
• ClinicalTrials.gov. A Phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed multiple myeloma (GMMG-HD6). NCT02495922. 2015 [cited 2016 Mar 4].
   Google Scholar
• ClinicalTrials.gov. Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma (CheckMate 602) (NCT02726581). NCT02726581. 2016 [cited 2016 Apr 6].
   Google Scholar